Ivan Jelcic

Title: Innovator Ivan Jelcic: Pioneering Polyomavirus Therapeutics

Introduction

Ivan Jelcic, based in Zurich, Switzerland, is an accomplished inventor with a remarkable portfolio of three patents. His innovative work has significantly contributed to the fields of virology and immunotherapy, focusing on therapeutic solutions for polyomavirus-related diseases.

Latest Patents

Jelcic's latest patents include groundbreaking research on recombinant human antibodies specifically designed for the therapy and prevention of polyomavirus-related diseases. These patents detail novel human-derived antibodies that specifically recognize polyomavirus polypeptides and have the capability to bind to key polyomaviruses such as the JC virus (JCV) and BK virus (BKV). Furthermore, the patents also encompass various methods, assays, and kits related to these antibodies, allowing for targeted immunotherapy and diagnostics in polyomavirus infections. The potential applications of these innovative antibodies range from pharmaceutical compositions to diagnostic tools.

Career Highlights

Throughout his career, Ivan Jelcic has collaborated with prominent institutions, including Neurimmune Holding AG and the University of Zurich. His experiences in these esteemed organizations have significantly enriched his research and development endeavors.

Collaborations

In his professional journey, Jelcic has worked alongside distinguished colleagues such as Jan Grimm and Roland Martin. Their collaborative efforts have undeniably advanced the understanding and treatment of polyomavirus-related conditions.

Conclusion

Ivan Jelcic stands out in the realm of scientific innovation with his impactful patents and collaborations. His dedication to developing targeted therapies for polyomavirus-related diseases is paving the way for new diagnostic and treatment options, ultimately enhancing patient care and outcomes in viral infections.